NF-κB localization in multiple myeloma plasma cells and mesenchymal cells

被引:12
作者
Conticello, Concetta [3 ]
Giuffrida, Raffaella [4 ]
Adamo, Luana [4 ]
Anastasi, Gabriele [4 ]
Martinetti, Daniela [4 ]
Salomone, Edvige [5 ]
Colarossi, Cristina [3 ]
Amato, Gabriella [3 ]
Gorgone, Ausilia [1 ]
Romano, Alessandra [1 ]
Iannolo, Gioacchin [4 ]
De Maria, Ruggero [6 ]
Giustolisi, Rosario [3 ]
Gulisano, Massimo [2 ,3 ]
Di Raimondo, Francesco [1 ]
机构
[1] Univ Catania, Dept Biomed Sci, Hematol Sect, I-95100 Catania, Italy
[2] Univ Catania, Dept Physiol Sci, I-95100 Catania, Italy
[3] Mediterranean Inst Oncol IOM, Dept Expt Oncol, Catania, Italy
[4] IOM Mediterranean Inst Oncol Ric, Catania, Italy
[5] Azienda Osped V Emanuele Ferrarotto S Bambino, Pathol Unit, Catania, Italy
[6] Ist Super Sanita, Dept Oncol & Mol Med, I-00161 Rome, Italy
关键词
Multiple myeloma; NF kappa B; Bortezomib; Mesenchymal cells; PROTEASOME INHIBITION; THERAPEUTIC TARGET; TUMOR-CELLS; INDUCED APOPTOSIS; GENE-EXPRESSION; BORTEZOMIB; ACTIVATION; PATHWAY; LEUKEMIA; KINASE;
D O I
10.1016/j.leukres.2010.06.023
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Several reports demonstrated that the activation of Nuclear Factor-kappa B NF-kappa B is essential for the pathogenesis of multiple myeloma (MM). We analyzed the nuclear localization of NF-kappa B in MM-cells derived from 60 different patients with MM at presentation and in relapse, as well as in three myeloma cell lines. Nuclear localization (the active form) of NF-kappa B was detected in only one MM-sample from a refractory patient and in two samples from relapsed patients, while all the other samples, including the MM-cell lines, almost exclusively express the cytoplasmic (inactive) form of NF-kappa B. In mesenchymal cells from MM-patients NF-kappa B was clearly present in the nucleus. In addition, the proteasome inhibitor Bortezomib, which is described to antagonize NF-kappa B activity, had a consistent antitumor activity against both chemoresistant and chemosensitive MM-cells, regardless the NF-kappa B localization, thus suggesting the existence of other molecular targets of proteasome inhibitors in MM. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:52 / 60
页数:9
相关论文
共 46 条
[11]   Captivating Bortezomib: An active but still mysterious drug [J].
Di Raimondo, Francesco ;
Conticello, Concetta .
LEUKEMIA RESEARCH, 2010, 34 (04) :411-412
[12]   BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-κB pathway [J].
Endo, Tomoyuki ;
Nishio, Mitsufumi ;
Enzler, Thomas ;
Cottam, Howard B. ;
Fukuda, Tetsuya ;
James, Danelle F. ;
Karin, Michael ;
Kipps, Thomas J. .
BLOOD, 2007, 109 (02) :703-710
[13]  
Feinman R, 1999, BLOOD, V93, P3044
[14]  
FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839
[15]   Targeting NF-κB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells [J].
Frelin, C ;
Imbert, V ;
Griessinger, E ;
Peyron, AC ;
Rochet, N ;
Philip, P ;
Dageville, C ;
Sirvent, A ;
Hummelsberger, M ;
Bérard, E ;
Dreano, M ;
Sirvent, N ;
Peyron, JF .
BLOOD, 2005, 105 (02) :804-811
[16]   Multiple myeloma:: Lusting for NF-κB [J].
Gilmore, Thomas D. .
CANCER CELL, 2007, 12 (02) :95-97
[17]  
HATA H, 1993, BLOOD, V81, P3357
[18]  
Hideshima T, 2001, CANCER RES, V61, P3071
[19]   NF-κB as a therapeutic target in multiple myeloma [J].
Hideshima, T ;
Chauhan, D ;
Richardson, P ;
Mitsiades, C ;
Mitsiades, N ;
Hayashi, T ;
Munshi, N ;
Dang, L ;
Castro, A ;
Palombella, V ;
Adams, J ;
Anderson, KC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (19) :16639-16647
[20]   MLN120B, a novel IκB kinase β inhibitor, blocks multiple myeloma cell growth in vitro and in vivo [J].
Hideshima, Teru ;
Neri, Paola ;
Tassone, Pierfranchesco ;
Yasui, Hiroshi ;
Ishitsuka, Kenji ;
Raje, Noopur ;
Chauhan, Dharminder ;
Podarl, Klaus ;
Mitsiades, Constantine ;
Dang, Lenny ;
Munshi, Nikhil ;
Richardson, Paul ;
Schenkein, David ;
Anderson, Kenneth C. .
CLINICAL CANCER RESEARCH, 2006, 12 (19) :5887-5894